data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
SPY
––%
QQQ
––%
BTC/USD
––%
DIA
––%
GLD
––%
TLT
––%
Inhibikase Therapeutics
(NASDAQ:IKT)
$0.50
-0.04[-7.41%]
At close: Dec 8(Delayed 15-Minutes)
Get Real Time Here
$0.52
0.0200[4.00%]
After Hours: 4:18PM EDT
Day Range0.477 - 0.54052 Wk Range0.440 - 1.800Open / Close0.530 / 0.500Float / Outstanding19.867M / 25.227M
Vol / Avg.146.944K / 100.091KMkt Cap12.614MP/E-50d Avg. Price0.730
Div / Yield (Forward)- / -%Payout Ratio-Total Float19.867MEPS-0.750

Inhibikase Therapeutics Stock (NASDAQ:IKT), Quotes and News Summary

Inhibikase Therapeutics Stock (NASDAQ: IKT) stock price, news, charts, stock research, profile.

Day Range0.477 - 0.54052 Wk Range0.440 - 1.800Open / Close0.530 / 0.500Float / Outstanding19.867M / 25.227M
Vol / Avg.146.944K / 100.091KMkt Cap12.614MP/E-50d Avg. Price0.730
Div / Yield (Forward)- / -%Payout Ratio-Total Float19.867MEPS-0.750
PRNewswire - 1 day ago
PRNewswire - Nov 22, 2022, 8:00AM
PRNewswire - Nov 14, 2022, 5:45PM
PRNewswire - Nov 8, 2022, 8:00AM
PRNewswire - Nov 7, 2022, 8:00AM
PRNewswire - Oct 12, 2022, 8:00AM
PRNewswire - Sep 21, 2022, 4:05PM
PRNewswire - Sep 15, 2022, 8:00AM
PRNewswire - Sep 8, 2022, 8:30AM
PRNewswire - Sep 1, 2022, 4:05PM
PRNewswire - Aug 26, 2022, 8:00AM
PRNewswire - Aug 23, 2022, 8:00AM
PRNewswire - Aug 12, 2022, 4:55PM
PRNewswire - Aug 8, 2022, 8:30AM
PRNewswire - Jun 13, 2022, 8:00AM
PRNewswire - May 16, 2022, 5:00PM
PRNewswire - May 10, 2022, 8:05AM
PRNewswire - May 9, 2022, 4:05PM
PRNewswire - Apr 21, 2022, 4:05PM
PRNewswire - Apr 6, 2022, 8:00AM
PRNewswire - Mar 31, 2022, 5:00PM
PRNewswire - Mar 28, 2022, 8:00AM
PRNewswire - Mar 25, 2022, 8:00AM
PRNewswire - Mar 23, 2022, 8:00AM
PRNewswire - Mar 8, 2022, 8:00AM
PRNewswire - Jan 5, 2022, 8:30AM
TipRanks - Nov 15, 2022, 5:05PM
Seeking Alpha - Nov 15, 2022, 9:55AM
InvestorsObserver - Nov 7, 2022, 11:34AM
Seeking Alpha - Nov 7, 2022, 11:16AM
InvestorsObserver - Aug 29, 2022, 12:12PM
Seeking Alpha - Aug 26, 2022, 8:36AM
InvestorsObserver - Aug 15, 2022, 1:02PM
Seeking Alpha - Aug 15, 2022, 11:11AM
TipRanks - Aug 15, 2022, 10:40AM
InvestorsObserver - Aug 10, 2022, 12:54PM
TipRanks - Jun 13, 2022, 9:55AM
Seeking Alpha - Jun 13, 2022, 8:58AM
TipRanks - May 20, 2022, 11:55AM
Seeking Alpha - May 17, 2022, 9:42AM
TipRanks - Apr 20, 2022, 3:55PM
InvestorsObserver - Apr 19, 2022, 9:46AM
Seeking Alpha - Apr 1, 2022, 11:09AM
TalkMarkets - Mar 28, 2022, 10:46AM
TipRanks - Mar 8, 2022, 11:05AM
InvestorsObserver - Mar 3, 2022, 9:52AM
InvestorsObserver - Dec 27, 2021, 10:07AM
InvestorsObserver - Dec 22, 2021, 10:48AM
Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.
Read More

Earnings

see more
Q3 2022Est.ActualSurprise
EPS-0.180-0.180 0.0000
REV200.000K7.291K-192.709K
Q2 2022Est.ActualSurprise
EPS-0.190-0.180 0.0100
REV300.000K6.552K-293.448K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Inhibikase Therapeutics (IKT) stock?

A

You can purchase shares of Inhibikase Therapeutics (NASDAQ: IKT) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Inhibikase Therapeutics's (IKT) competitors?

A

There are no as such competitors for Inhibikase Therapeutics.

Q

What is the target price for Inhibikase Therapeutics (IKT) stock?

A

The latest price target for Inhibikase Therapeutics (NASDAQ: IKT) was reported by JonesTrading on Wednesday, November 16, 2022. The analyst firm set a price target for 0.00 expecting IKT to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Inhibikase Therapeutics (IKT)?

A

The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $0.5 last updated December 8, 2022, 9:00 PM UTC.

Q

Does Inhibikase Therapeutics (IKT) pay a dividend?

A

There are no upcoming dividends for Inhibikase Therapeutics.

Q

When is Inhibikase Therapeutics (NASDAQ:IKT) reporting earnings?

A

Inhibikase Therapeutics’s Q3 earnings are confirmed for Monday, November 14, 2022.

Q

Is Inhibikase Therapeutics (IKT) going to split?

A

There is no upcoming split for Inhibikase Therapeutics.

Q

What sector and industry does Inhibikase Therapeutics (IKT) operate in?

A

Inhibikase Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.